BioAtla reports Q4 net loss $14.9M, cuts workforce 30% to extend runway to 1H 2026 clinical readouts

BioAtla, Inc.

Net loss $14.9M in Q4 2024 vs $26.9M Q4 2023; cash $49.0M at year-end vs $111.5M.
Workforce reduction of over 30%; estimated $0.5-$0.6M in severance costs mostly in Q2 2025.
BA3182 (CAB-EpCAM x CAB-CD3) Phase 1 dose escalation ongoing; data readout mid-2025; expansion data 1H 2026.
Mecbotamab vedotin (CAB-AXL-ADC): 66% 1-year OS, 58% 2-year OS in mKRAS NSCLC; median OS not reached.
Ozuriftamab vedotin (CAB-ROR2-ADC): 45% ORR (confirmed/unconfirmed) in HPV+ SCCHN; partnering discussions Q1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.